Bioinvent Presents Combined BI-1808 and KEYTRUDA Data for Ovarian Cancer
What happened
Bioinvent presented updated efficacy results for its BI-1808 therapy combined with MSD’s KEYTRUDA® at the ESMO Congress in Madrid. The analysis, which includes 34 evaluable patients, focused on patients with advanced platinum-resistant recurrent ovarian cancer receiving a chemotherapy-free regimen. BI-1808 is an anti-TNFR2 antibody designed to deplete immunosuppressive cells and promote anti-tumoral T-cell activity.
From investegate.co.uk
Why it matters
The presentation validates the joint therapeutic effort between Bioinvent and MSD. The results provide updated information on the efficacy of combining BI-1808 with KEYTRUDA in treating PRROC. The study is ongoing, with a randomized Part C planned to incorporate BI-1808 into the new standard of care.
From investegate.co.uk
Who's involved
- BioinventLead developer of the BI-1808 anti-TNFR2 antibody.
- MSDProvider of the anti-PD-1 therapy KEYTRUDA®.
- European Society for Medical OncologyProfessional organization hosting the congress.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
Keep exploring
The entities involved
-
Bioinvent
Swedish clinical-stage biotech company
Nothing else this week.
-
Merck KGaA
German multinational science and technology company